Nuevas recomendaciones | 10 AGO 19

Dolor neuropático

El dolor neuropático es aquel causado por una lesión o enfermedad del sistema nervioso somatosensorial. Se actualizaron las recomendaciones para su tratamiento según nuevas evidencias
INDICE:  1. Página 1 | 2. Página 1
Página 1

Referencias 

1. International Association for the Study of Pain. Epidemiology of neuropathic pain: how common is neuropathic pain, and what is its impact? Washington: IASP; 2014. https://www.iasp-pain.org/Advocacy/Content. aspx?ItemNumber=3934 [cited 2018 May 1]

2. Pain Management Network [Internet]. Sydney: Agency for Clinical Innovation; 2018 www.aci.health.nsw.gov.au/chronicpain [cited 2018 May 1]

3. International Association for the Study of Pain. IASP Taxonomy. Pain terms. Neuropathic pain. Updated 2017 Dec 14. www.iasp-pain.org/Taxonomy#Neuropathicpain [cited 2018 May 1]

4. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73. https://doi.org/10.1016/S1474-4422(14)70251-0

5. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011;152:2204-5. https://doi.org/10.1016/j.pain.2011.06.017

6. Oaklander AL, Wilson PR, Moskovitz PA, Manning DC, Lubenow T, Levine JD, et al. Response to “A new definition of neuropathic pain”. Pain 2012;153:934-5. https://doi.org/ 10.1016/j.pain.2012.01.012

7. Javed S, Alam U, Malik RA. Treating diabetic neuropathy: present strategies and emerging solutions. Rev Diabet Stud 2015;12:63-83. https://doi.org/10.1900/RDS.2015.12.63

8. Centner CM, Little F, Van Der Watt JJ, Vermaak JR, Dave JA, Levitt NS, et al. Evolution of sensory neuropathy after initiation of antiretroviral therapy. Muscle Nerve 2018;57:371-

9. https://doi.org/10.1002/mus.25710 9. Centner CM, Bateman KJ, Heckmann JM. Manifestations of HIV infection in the peripheral nervous system. Lancet Neurol 2013;12:295-309. https://doi.org/10.1016/ S1474-4422(13)70002-4

10. Pharmaceutical Benefits Scheme. PBAC Public Summary Documents – March 2015. Lignocaine; 5% patch: dermal, 30; Versatis. www.pbs.gov.au/info/industry/listing/elements/ pbac-meetings/psd/pbac-public-summary-documentsmarch-2015 [cited 2018 May 1]

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024